The IOL-VIP system: restoring sight to AMD patients

Article

Dr José Luis Menezo looks at improving the visual acuity of patients with age-related macular degeneration (AMD) using an IOL-Vip system.

Key Points

The most commonly used low-vision device, the intraocular miniaturized telescope (IMT), confines the area of vision to a 20-degree angle at the central visual field and relies on the fellow eye to preserve the peripheral visual field. This, in my opinion, is not ideal. By contrast, the IOL-VIP (intraocular lens for visually impaired people) system, first presented in Florence in 2003,1 offers a better alternative. It does not compromise the peripheral visual field (leaving an area of approximately 80º) and can be implanted in both eyes, maintaining binocular vision.

A cross-discipline group of researchers from both the Medical University and the Physics University of Valencia2 presented a pilot study of the IOL VIP system in a series of 19 eyes at the 2008 ESCRS meeting in Berlin.3 The data gained from this pilot study were compared with the theoretical values obtained in a previous study.4

The cornea:anterior chamber lens distance and the anterior chamber lens:posterior chamber lens distance were both evaluated with high-frequency ultrasound biomicroscopy (UBM). Endothelial cell count was measured using a specular microscope preoperatively and 18 months postoperatively.

No complications were observed

Of the 19 patients enrolled in the pilot study, no cases of intraoperative or postoperative complications were detected, and no patients presented severe adverse effects. Four patients presented increased intraocular hypertension and a mild sectorial corneal oedema, controlled with topical timolol maleate. Only three patients developed posterior capsular opacification during the course of the study, which were treated with neodymium YAG laser. A single patient requested removal of the device after experiencing what was subjectively and confusedly described as a "strange situation" mixed with dizziness, but without diplopia. The refractive results in this patient were satisfactory; nevertheless, both lenses were removed and a standard monofocal lens was reimplanted.

Related Videos
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
© 2024 MJH Life Sciences

All rights reserved.